Core Viewpoint - The legal opinion confirms that the 2024 Annual General Meeting of Ruikang Pharmaceutical Group Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][11]. Group 1: Meeting Procedures - The meeting was convened based on resolutions from the 14th and 16th meetings of the fifth board of directors held on April 23 and May 6, 2025, respectively [2]. - The notice for the meeting and a supplementary notice were published on April 24 and May 7, 2025, in various financial newspapers and on the official website [2][3]. Group 2: Attendance and Qualifications - The equity registration date for the meeting was May 9, 2025, with a total of 1 shareholder present, representing 185,491,897 shares, which is 12.3274% of the total voting shares [3][4]. - Additionally, 300 shareholders participated via online voting, representing 11,644,879 shares, or 0.7739% of the total voting shares [4]. Group 3: Agenda Items - The agenda included the following items: 1. 2024 Annual Report and its summary 2. 2024 Board of Directors' Work Report 3. 2024 Financial Settlement Report 4. 2024 Supervisory Board Work Report 5. Proposal for the board to issue shares to specific targets via simplified procedures, which requires a special resolution [4][5]. Group 4: Voting Process and Results - The voting was conducted through a combination of on-site written voting and online voting, adhering to legal and regulatory requirements [5][11]. - The voting results showed that 190,902,607 shares (96.8376%) were in favor, 4,593,560 shares (2.3301%) opposed, and 1,640,609 shares (0.8322%) abstained [6][9]. - For minority investors, 5,410,710 shares (46.4643%) were in favor, while 4,593,560 shares (39.4470%) opposed, and 1,640,609 shares (14.0887%) abstained [6][8]. Group 5: Conclusion - The legal opinion concludes that the meeting's procedures, attendance qualifications, and voting processes complied with the Company Law and relevant regulations, affirming the validity of the resolutions passed [11][12].
瑞康医药: 2024年年度股东大会的律师见证法律意见书